Liquid Biopsy Market

The global liquid biopsy market size was valued at USD 2.60 Billion in 2025 and is projected to reach USD 7.61 Billion by 2034, exhibiting a CAGR of 12.31% during the forecast period 2026-2034. Rising global cancer burden, rapid advances in next-generation sequencing (NGS), expanding precision oncology adoption, and growing demand for non-invasive early detection are driving the liquid biopsy market growth. Kits and Reagents lead the product segment at 46.9% in 2025, while Circulating Tumor Cells dominate the biomarker segment at 33.7%. North America accounts for 38.6% of global revenue in 2025, the world's largest regional market.

Market Snapshot

The liquid biopsy market's growth trajectory from 2020 through 2034 reflects consistent historical expansion and a sharply accelerating forecast curve, supported by precision oncology adoption, ctDNA reimbursement, and NGS-based multi-cancer early detection rollouts.

To get more information on this market, Request Sample

Segment-level CAGR comparisons highlight Kits and Reagents and Asia-Pacific as the fastest-growing sub-categories through 2034, reflecting the expanding test adoption curve in emerging oncology markets.

The liquid biopsy market is transforming rapidly, driven by precision oncology, NGS innovation, and growing clinical adoption of non-invasive diagnostics. Valued at USD 2.60 Billion in 2025, it is forecast to reach USD 7.61 Billion by 2034 at a CAGR of 12.31%. Per WHO, cancer caused nearly 10 million deaths globally in 2022, fuelling demand for earlier, less invasive detection.

Kits and Reagents lead the product segment at 46.9% in 2025, supported by recurring demand for ctDNA extraction kits and NGS library preparation. Platforms and Instruments follow at 29.8%, benefitting from rising NGS installations, while Services at 23.3% reflect growing outsourced testing by hospitals and oncology clinics.

North America leads with a 38.6% global revenue share in 2025, anchored by FDA-cleared liquid biopsy approvals and broad Medicare/private payer reimbursement. Europe holds 26.9%, while Asia-Pacific, at 22.4%, is the fastest-growing region, propelled by oncology infrastructure expansion in China, Japan, and India. The competitive landscape is concentrated among F. Hoffmann-La Roche Ltd, Guardant Health Inc., Illumina Inc., and Thermo Fisher Scientific Inc.

Key Market Insights

Key Analytical Observations Supporting the Above Data:

• Kits and Reagents' 46.9% dominance in 2025 reflects recurring per-test economics, with each workflow consuming USD 300-800 in cfDNA extraction and NGS library prep reagents.
• Circulating Tumor Cells lead the biomarker segment at 33.7% in 2025, supported by CellSearch FDA-approved platforms in breast, prostate, and colorectal cancer monitoring.
• North America's 38.6% share in 2025 is anchored by FDA approvals of Guardant360 CDx and Epi proColon, and broad CMS reimbursement for genomic profiling.

Liquid biopsy is a minimally invasive diagnostic approach that analyses tumour-derived components circulating in body fluids, primarily blood, but also urine, saliva, and cerebrospinal fluid. It captures circulating tumour cells (CTCs), circulating tumour DNA (ctDNA), extracellular vesicles, and tumour-educated platelets to support cancer screening, diagnosis, companion diagnostics, and treatment monitoring.

Applications span the oncology care pathway: early screening, therapy selection, minimal residual disease detection, recurrence surveillance, and emerging uses in transplant rejection monitoring and prenatal testing. Clinical adoption is supported by regulatory clearances, payer reimbursement, and clinical guideline inclusion.

Macroeconomic enablers include the global cancer burden, which GLOBOCAN 2022 estimates at 19.97 million new cases and projects at 35 million by 2050, oncology R&D spending, and over 30,000 NGS instruments installed worldwide. Favourable reimbursement, particularly CMS coverage for comprehensive genomic profiling, further strengthens market expansion.

To evaluate market opportunities, Request Sample

Market Drivers

• Rising Global Cancer Burden: GLOBOCAN 2022 estimated 19.97 million new cancer cases globally, with incidence projected to surpass 35 million by 2050. This structural rise directly expands the liquid biopsy's demand base.
• Precision Oncology and Companion Diagnostics: Over 100 FDA-approved targeted therapies require molecular profiling, with ~40% now accepting liquid biopsy as an alternative to tissue.
• NGS Cost Reduction: Sequencing cost dropped in consecutive years, making comprehensive genomic profiling economically viable across community oncology.
• Multi-Cancer Screening: MCED tests such as GRAIL's Galleri can detect 50+ cancer types from a single blood draw.

Market Restraints

• Reimbursement Coverage Gaps: Coverage for early detection, MRD monitoring, and non-FDA-approved indications remains inconsistent across private payers in the US and Europe.
• High Test Cost: Premium panels range from USD 3,000 to USD 5,500 per test, limiting adoption in price-sensitive emerging markets and non-reimbursed screening.
• Clinical Validation Challenges: Detecting low-fraction ctDNA in early-stage cancers remains difficult, with sensitivity often below 50% in stage I disease.

Market Opportunities

• Minimal Residual Disease Monitoring: Post-treatment ctDNA surveillance is the highest-growth application, with Signatera and NeoGenomics' RaDaR targeting a USD 1.5-2 Billion opportunity by 2030.
• Expansion Beyond Oncology: Transplant rejection monitoring, non-invasive prenatal testing, and infectious disease diagnostics leverage the same cfDNA infrastructure.
• Emerging Market Penetration: China, India, and Brazil are structurally underpenetrated, where national screening programmes create multi-billion-dollar expansion potential.

Market Challenges

• Regulatory Complexity: Navigating FDA, EMA (IVDR), NMPA, and PMDA pathways adds significant time and cost, with IVDR compliance alone adding 2-3 years of European market preparation.
• Data Standardization: Inter-laboratory variability in ctDNA quantification and variant calling remains a structural barrier to guideline integration.

1. Multi-Cancer Early Detection (MCED) Commercialization

MCED tests screening 50+ cancer types from a single blood draw are moving from pilot deployments to commercial rollout. GRAIL's Galleri, Exact Sciences' Cologuard Plus, and Freenome's pipeline represent the reference footprint, with NHS England's 140,000-participant Galleri trial supporting broader adoption.

2. ctDNA-Based Minimal Residual Disease Monitoring

MRD monitoring post-surgery or chemotherapy is the fastest-growing clinical application in 2025, with Natera's Signatera, Guardant Reveal, and NeoGenomics' RaDaR competing for standard-of-care integration across adjuvant protocols.

3. AI and Machine Learning in Variant Interpretation

AI models are increasingly deployed in variant calling, fragmentomics, and methylation signature interpretation. Delfi Diagnostics' FirstLook lung cancer test leverages AI-based fragmentomics as its core differentiation.

4. Extracellular Vesicle and Exosome Diagnostics

EV-based liquid biopsy is a complementary approach to ctDNA, offering enhanced protein and RNA content. Bio-Techne, Exosome Diagnostics, and Caris lead commercial development, with ExoDx Prostate IntelliScore as the first FDA-breakthrough EV diagnostic.

5. Methylation-Based Cancer Detection

DNA methylation signature profiling, pioneered by GRAIL and Bluestar Genomics, is moving from research to commercial deployment. Methylation tests offer superior tissue-of-origin accuracy versus mutation-only panels.

The liquid biopsy value chain integrates reagent suppliers, instrument platforms, diagnostic laboratories, and healthcare providers into a cohesive workflow spanning sample collection through clinical report delivery. Each stage contributes a distinct margin, differentiation, and technology investment profile.

Assay developers occupy the highest-value position by integrating IP-protected bioinformatics, clinical validation, and regulatory clearances into defensible platforms. However, they face margin pressure from instrument vendors commoditizing workflow costs and from vertically integrated labs internalising assay development.

Next-Generation Sequencing (NGS) Platforms

NGS is the backbone of liquid biopsy, with Illumina commanding over 70% installed base share in 2025 via NovaSeq X, NextSeq 2000, and MiSeq. Thermo Fisher's Ion Torrent serves targeted panel workflows, while Element Biosciences and PacBio add alternative chemistries.

Digital PCR and Droplet-Based Detection

Bio-Rad's QX600 Droplet Digital PCR and Thermo Fisher's QuantStudio Absolute Q are reference platforms for sensitive ctDNA mutation detection below 0.01% allele frequency, ideal for MRD applications.

Methylation and Fragmentomics

Methylation profiling using bisulfite conversion or enzymatic methyl sequencing enables multi-cancer detection via signature patterns. Fragmentomics is an emerging AI-driven approach pioneered by Delfi Diagnostics.

AI-Driven Bioinformatics

Machine learning is standard in variant calling, noise filtering, and tissue-of-origin prediction. Tempus Labs, Caris, and GRAIL deploy proprietary AI pipelines integrating genomic, methylomic, and clinical outcomes data.

By Product and Service

Kits and Reagents command a 46.9% majority share in 2025, supported by the recurring per-test consumable economics of liquid biopsy workflows. Every clinical test consumes USD 300-800 in extraction kits, library preparation reagents, and enzymes, creating a revenue base that grows in lockstep with test volume. QIAGEN, Thermo Fisher, and Roche lead this segment.

To access detailed market analysis, Request Sample

Platforms and Instruments at 29.8% in 2025 represent the capital-equipment layer, dominated by Illumina's NovaSeq and NextSeq. Services at 23.3% capture outsourced clinical testing volume handled by specialty labs such as Guardant Health, Natera, and NeoGenomics.

By Circulating Biomarker

Circulating Tumor Cells (CTCs) dominate at 33.7% in 2025, benefitting from established FDA-cleared platforms such as Menarini Silicon Biosystems' CellSearch for breast, prostate, and colorectal cancer monitoring. The segment reflects over two decades of clinical validation.

Circulating Tumor DNA at 28.6% in 2025 is the fastest-growing biomarker at ~14.2% CAGR, propelled by ctDNA-based MRD and comprehensive genomic profiling. Extracellular Vesicles at 21.4% are gaining traction in prostate, pancreatic, and lung cancer. Others (16.3%) include tumour-educated platelets, circulating RNA, and cell-free proteins.

Regional Market Insights

North America commands a 38.6% global revenue share in 2025, the most dominant regional position in the global liquid biopsy market. The United States is the anchor, supported by FDA approvals for Guardant360 CDx, FoundationOne Liquid CDx, Epi proColon, and GRAIL's Galleri. CMS National Coverage Determination provides universal Medicare reimbursement for eligible advanced cancer patients.

Europe holds 26.9% in 2025, with the IVDR framework providing harmonised approval pathways across the EU-27. Germany, France, and the UK account for roughly 65% of European demand.

Asia-Pacific at 22.4% in 2025 is the fastest-growing region at ~15.6% CAGR, propelled by China's NMPA approvals for domestic products from BGI Genomics, Burning Rock, and Genetron Health. Japan's Precision Medicine Initiative and India's Ayushman Bharat oncology expansion add further growth vectors.

Competitive Landscape

The competitive landscape features diversified global leaders (Roche, Illumina, QIAGEN, Thermo Fisher) with broad reagent, platform, and assay portfolios, alongside focused pure-play innovators (Guardant Health, Natera, GRAIL) specialising in clinical-grade ctDNA applications and MRD monitoring.

F. Hoffmann-La Roche Ltd

Roche is the global leader in in-vitro diagnostics, combining a broad liquid biopsy portfolio spanning ctDNA assays, companion diagnostics, and integrated pharma-diagnostic co-development through Genentech. The 2018-closed Foundation Medicine acquisition anchors its comprehensive genomic profiling leadership.

• Product & Platform Portfolio: AVENIO ctDNA Analysis Kits, cobas EGFR Mutation Test, FoundationOne Liquid CDx.
• Recent Developments: In September 2023, Roche France, Foundation Medicine, Inc., and the Institut Gustave Roussy announced a unique partnership to establish in-house liquid biopsy testing at the Institut Gustave Roussy’s facilities in France, by transferring technology from Foundation Medicine’s FoundationOne®Liquid CDx, a blood-based comprehensive genomic profiling (CGP) test.
• Strategic Focus: Leveraging the Roche-Genentech-Foundation Medicine value chain to pair companion diagnostics with targeted therapies, expand AVENIO in decentralised hospital labs, and grow ctDNA-based MRD services globally.

Guardant Health, Inc.

Guardant Health is the pure-play leader in ctDNA comprehensive genomic profiling. Guardant360 CDx is a reference FDA-approved companion diagnostic for advanced solid tumours. The company operates a fully integrated CLIA-certified laboratory model with direct oncologist engagement.

• Product & Platform Portfolio: Guardant360 CDx, Guardant360 TissueNext, Guardant Reveal (MRD), Shield (colorectal cancer screening).
• Recent Developments: In July 2024, the FDA approved Guardant Health's Shield blood test for primary colorectal cancer screening in average-risk adults aged 45 and older, expanding the addressable market beyond advanced cancer into population screening.
• Strategic Focus: Expanding Shield for broad colorectal screening reimbursement, scaling Reveal for MRD monitoring across solid tumour indications, and growing pharma collaboration revenue through companion diagnostic partnerships.

Illumina, Inc.

Illumina commands over 70% of the global NGS installed base in 2025 and is the dominant sequencing platform provider for liquid biopsy. Beyond instruments, Illumina develops its own liquid biopsy assays through the TruSight Oncology (TSO) portfolio.

• Product & Platform Portfolio: NovaSeq X, NextSeq 2000, MiSeq, TruSight Oncology 500 ctDNA, TruSight Oncology Comprehensive.
• Recent Developments: In November 2024, Illumina, Inc. announced that it will release TruSight Oncology 500 v2 (TSO 500 v2), a new version of its flagship cancer research assay to enable comprehensive genomic profiling (CGP). The assay is currently under development, with global release planned for mid-2025.
• Strategic Focus: Consolidating NGS platform dominance via NovaSeq X volume expansion, growing the TSO 500 ctDNA footprint in distributed clinical testing, and enabling third-party assay developers through integrated workflow solutions.

The global liquid biopsy market is moderately concentrated, with the top 5 players (Roche, Guardant Health, Illumina, QIAGEN, Thermo Fisher) accounting for approximately 42-48% of global revenue in 2025. The remainder is distributed across specialised diagnostic developers (Natera, NeoGenomics, GRAIL) and regional champions.

The market has a bifurcated structure: established reagent and platform giants leverage broad infrastructure scale, while pure-play innovators compete on assay sensitivity, clinical validation depth, and oncology specialty focus. Consolidation trends include Roche's Foundation Medicine integration, Illumina's GRAIL divestiture, and ongoing M&A among mid-tier laboratory service providers.

Fastest-Growing Segments

Asia-Pacific liquid biopsy services grow at ~15.6% CAGR through 2034, the fastest regional path, driven by China's oncology infrastructure expansion and Japan's precision medicine reimbursement. Kits and Reagents grow at ~13.5% CAGR, while ctDNA biomarker assays grow at ~14.2% CAGR.

Emerging Market Expansion

Multi-cancer early detection is the largest single opportunity, targeting a USD 2+ Billion addressable market by 2030. ctDNA-based MRD monitoring is the second-largest opportunity at USD 1.5-2 Billion by 2030.

Venture and Private Investment Trends

Cumulative venture and growth equity investment in liquid biopsy exceeded USD 12 Billion between 2020 and 2025 per PitchBook data, with notable transactions including GRAIL's separation from Illumina, Natera's Signatera financing, and Asia-Pacific rounds in BGI Genomics, Burning Rock, and Singlera Genomics.

The global liquid biopsy market forecast projects expansion from USD 2.60 Billion in 2025 to USD 7.61 Billion by 2034 at a CAGR of 12.31%, a near-tripling of market value supported by multi-cancer early detection commercialization, MRD standard-of-care integration, and Asia-Pacific regional penetration.

Three structural shifts will reshape the industry through 2034. First, multi-cancer early detection will transition from pilot programmes to reimbursed population-scale deployment. Second, ctDNA-based MRD monitoring will become standard-of-care post-surgical decision support across colorectal, breast, and lung adjuvant protocols.

Third, AI-driven bioinformatics and methylation/fragmentomics will enable next-generation multi-modal liquid biopsy platforms combining mutation, methylation, protein, and fragment-size signatures into unified diagnostic outputs. By 2034, liquid biopsy is forecast to complete its transition from specialised companion diagnostics into a mainstream pillar of global cancer care infrastructure.

Primary Research

Primary research included over 55 structured interviews in 2024-2025 with senior executives at Tier-1 diagnostic developers, oncology clinical directors at major US and European cancer centres, reference laboratory directors, payer policy specialists, and institutional investors. Primary insights validated market sizing, segmentation breakdowns, adoption timelines, and competitive positioning.

Secondary Research

Secondary sources include IARC GLOBOCAN 2022 cancer statistics, WHO burden reports, US FDA device approval databases, CMS coverage determinations, EMA/IVDR publications, NMPA approvals, company annual reports, and trade publications, including GenomeWeb and 360Dx.

Forecasting Models

Market size estimates and growth projections were derived using a blended top-down and bottom-up forecasting approach, incorporating cancer incidence projections, test adoption curves, pricing evolution, and reimbursement modelling. Base, optimistic, and conservative scenarios were developed to reflect regulatory and reimbursement uncertainty.

Liquid Biopsy Market Report Scope

Key Benefits for Stakeholders:

• IMARC’s report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the liquid biopsy market from 2020-2034.
• The research study provides the latest information on the market drivers, challenges, and opportunities in the global liquid biopsy market.
• The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
• Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the liquid biopsy industry and its attractiveness.
• Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.